Our Commitment to the CF Community
June 1, 2021
As Cystic Fibrosis (CF) Awareness Month comes to a close, we are taking time to reflect on the commitment of the CF community to find treatments for 100% of people with CF. You are an unstoppable community that doesn’t know the meaning of giving up, and one that always rises up to new challenges. Your […]
VIDEO: How Translate Bio Harnesses the Power of mRNA to Develop Potentially Transformative Medicines
January 14, 2021
This spotlight takes a closer look at our new animation that shows how mRNA therapies and vaccines work, and why they may be ideal for treating genetic diseases such as cystic fibrosis, or preventing infectious diseases such as COVID-19.
#mRNAallday: 2020 is the Year mRNA Became a Household Term
December 30, 2020
2020 has been an absolutely unprecedented year. There is no denying that we are living through historic times as we continue to navigate the COVID-19 pandemic. And while this year will be remembered for a host of reasons, for those of us who are passionate about mRNA science, 2020 marks a transformative moment in time.
The Magic Line: A Virtual Campaign to Conquer the Final CF Summit
December 29, 2020
At Translate Bio, bringing the patient voice and experience into our daily work is of critical importance to us. This month, we are very proud to sponsor and support “The Magic Line,” a month-long campaign organized by Emily’s Entourage.
Celebrating Our Chief Scientific Officer, Dr. Richard Wooster, 25 Years After the Discovery of the BRCA2 Gene
December 21, 2020
25 years ago, our Chief Scientific Officer, Dr. Richard Wooster, was part of a historic scientific discovery. In December 1995, a team of researchers at The Institute of Cancer Research (ICR), London, published a paper identifying the second breast cancer susceptibility gene, better known as BRCA2. Translate Bio’s Chief Scientific Officer, Dr. Richard Wooster, was […]
Leveraging RNA and Delivery Expertise to Treat Pulmonary Diseases
August 18, 2020
This spotlight delves into how our mRNA and delivery expertise may enable us to treat three other pulmonary diseases: primary ciliary dyskinesia (PCD), pulmonary arterial hypertension (PAH), and idiopathic pulmonary fibrosis (IPF). We aim to address the underlying cause of diseases using our technology to develop novel treatment options to improve the lives of people living with serious, life threatening lung diseases.
Social Distancing and Togetherness: A Contradiction in Terms?
May 18, 2020
This spotlight takes a departure on our usual science-focus to take a closer look at the challenges, and norms, of social distancing for people with cystic fibrosis. Translate Bio's Maura Gavaghan spoke with CF advocate, mom and teacher Colleen Veitengruber to understand how she is navigating this unprecedented time and the impact this is having on her family.
The Promise of mRNA Vaccines
February 10, 2020
Translate Bio’s Chief Technology Officer, Frank DeRosa, co-authored a review published in npj Vaccines: The promise of mRNA vaccines: a biotech and industrial perspective. Here, Dr. DeRosa answers questions on this topic in the context of Translate’s partnership with Sanofi Pasteur to develop mRNA vaccines for infectious diseases. In March, 2020, both companies announced a […]
Sending the Message: mRNA’s Potential to Give the Body Instructions to Restore Health
January 10, 2020
Translate Bio’s Chief Medical Officer, Dr. Ann Barbier, shares her thoughts on why mRNA therapy may be ideal for treating genetic diseases that are caused by defective or missing proteins.
What a Difference a Decade Makes
September 22, 2019
Dr. Michael Heartlein, founder of Translate Bio's MRT platform, summarizes how more than a decade of pioneering mRNA as a therapeutic has solidified Translate’s understanding of mRNA therapy and our approach to drug development today.